APO Research
Talk to an analyst

APO RESEARCH · REPORT

Single-target Anti-VEGF Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Single-target Anti-VEGF Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025185 pages

Choose your research edition.

Industry ResearchSingle-target Anti-VEGF Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Single-target Anti-VEGF Drugs Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Single-target Anti-VEGF Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Single-target Anti-VEGF Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Single-target Anti-VEGF Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Single-target Anti-VEGF Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Single-target Anti-VEGF Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Single-target Anti-VEGF Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Single-target Anti-VEGF Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Single-target Anti-VEGF Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Single-target Anti-VEGF Drugs include Roche, Chengdu Kanghong Pharmaceutical, Samsung Bioepis, Regeneron Pharmaceuticals, Novartis, Coherus BioSciences and Biocon Biologics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Single-target Anti-VEGF Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Single-target Anti-VEGF Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Single-target Anti-VEGF Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Single-target Anti-VEGF Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Single-target Anti-VEGF Drugs Segment by Company

Roche

Chengdu Kanghong Pharmaceutical

Samsung Bioepis

Regeneron Pharmaceuticals

Novartis

Coherus BioSciences

Biocon Biologics

Single-target Anti-VEGF Drugs Segment by Type

Ranibizumab

Conbercept

Faricimab

Brolucizumab

Aflibercept

Other

Single-target Anti-VEGF Drugs Segment by Application

Diabetic Retinopathy

Age-related Macular Degeneration

Other

Single-target Anti-VEGF Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Single-target Anti-VEGF Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Single-target Anti-VEGF Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Single-target Anti-VEGF Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Single-target Anti-VEGF Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Single-target Anti-VEGF Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Single-target Anti-VEGF Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Single-target Anti-VEGF Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Single-target Anti-VEGF Drugs Industry Trends Table 2. Single-target Anti-VEGF Drugs Industry Drivers Table 3. Single-target Anti-VEGF Drugs Industry Opportunities and Challenges Table 4. Single-target Anti-VEGF Drugs Industry Restraints Table 5. Global Single-target Anti-VEGF Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Single-target Anti-VEGF Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Single-target Anti-VEGF Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Single-target Anti-VEGF Drugs Sales Market Share by Manufacturers Table 9. Global Single-target Anti-VEGF Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Single-target Anti-VEGF Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Single-target Anti-VEGF Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Single-target Anti-VEGF Drugs Manufacturers, Product Type & Application Table 13. Global Single-target Anti-VEGF Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Single-target Anti-VEGF Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Ranibizumab Table 17. Major Manufacturers of Conbercept Table 18. Major Manufacturers of Faricimab Table 19. Major Manufacturers of Brolucizumab Table 20. Major Manufacturers of Aflibercept Table 21. Major Manufacturers of Other Table 22. Global Single-target Anti-VEGF Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Single-target Anti-VEGF Drugs Sales by Type (2021-2026) & (K Units) Table 24. Global Single-target Anti-VEGF Drugs Sales by Type (2027-2032) & (K Units) Table 25. Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2021-2026) Table 26. Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2027-2032) Table 27. Global Single-target Anti-VEGF Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Single-target Anti-VEGF Drugs Revenue by Type (2021-2026) & (K Units) Table 29. Global Single-target Anti-VEGF Drugs Revenue by Type (2027-2032) & (K Units) Table 30. Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2021-2026) Table 31. Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Diabetic Retinopathy Table 33. Major Manufacturers of Age-related Macular Degeneration Table 34. Major Manufacturers of Other Table 35. Global Single-target Anti-VEGF Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Single-target Anti-VEGF Drugs Sales by Application (2021-2026) & (K Units) Table 37. Global Single-target Anti-VEGF Drugs Sales by Application (2027-2032) & (K Units) Table 38. Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2021-2026) Table 39. Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2027-2032) Table 40. Global Single-target Anti-VEGF Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Single-target Anti-VEGF Drugs Revenue by Application (2021-2026) & (K Units) Table 42. Global Single-target Anti-VEGF Drugs Revenue by Application (2027-2032) & (K Units) Table 43. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2021-2026) Table 44. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2027-2032) Table 45. Global Single-target Anti-VEGF Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Single-target Anti-VEGF Drugs Sales by Region (2021-2026) & (K Units) Table 47. Global Single-target Anti-VEGF Drugs Sales Market Share by Region (2021-2026) Table 48. Global Single-target Anti-VEGF Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Single-target Anti-VEGF Drugs Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Single-target Anti-VEGF Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 52. North America Single-target Anti-VEGF Drugs Sales by Country (2027-2032) & (K Units) Table 53. Europe Single-target Anti-VEGF Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 55. Europe Single-target Anti-VEGF Drugs Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Single-target Anti-VEGF Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Single-target Anti-VEGF Drugs Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Single-target Anti-VEGF Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Single-target Anti-VEGF Drugs Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Single-target Anti-VEGF Drugs Sales by Country (2027-2032) & (K Units) Table 62. Global Single-target Anti-VEGF Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Single-target Anti-VEGF Drugs Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Single-target Anti-VEGF Drugs Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Single-target Anti-VEGF Drugs Revenue Market Share by Region (2021-2026) Table 66. Global Single-target Anti-VEGF Drugs Revenue Market Share by Region (2027-2032) Table 67. Roche Company Information Table 68. Roche Business Overview Table 69. Roche Single-target Anti-VEGF Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Roche Single-target Anti-VEGF Drugs Product Portfolio Table 71. Roche Recent Development Table 72. Chengdu Kanghong Pharmaceutical Company Information Table 73. Chengdu Kanghong Pharmaceutical Business Overview Table 74. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product Portfolio Table 76. Chengdu Kanghong Pharmaceutical Recent Development Table 77. Samsung Bioepis Company Information Table 78. Samsung Bioepis Business Overview Table 79. Samsung Bioepis Single-target Anti-VEGF Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Samsung Bioepis Single-target Anti-VEGF Drugs Product Portfolio Table 81. Samsung Bioepis Recent Development Table 82. Regeneron Pharmaceuticals Company Information Table 83. Regeneron Pharmaceuticals Business Overview Table 84. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product Portfolio Table 86. Regeneron Pharmaceuticals Recent Development Table 87. Novartis Company Information Table 88. Novartis Business Overview Table 89. Novartis Single-target Anti-VEGF Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Novartis Single-target Anti-VEGF Drugs Product Portfolio Table 91. Novartis Recent Development Table 92. Coherus BioSciences Company Information Table 93. Coherus BioSciences Business Overview Table 94. Coherus BioSciences Single-target Anti-VEGF Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Coherus BioSciences Single-target Anti-VEGF Drugs Product Portfolio Table 96. Coherus BioSciences Recent Development Table 97. Biocon Biologics Company Information Table 98. Biocon Biologics Business Overview Table 99. Biocon Biologics Single-target Anti-VEGF Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Biocon Biologics Single-target Anti-VEGF Drugs Product Portfolio Table 101. Biocon Biologics Recent Development Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. Single-target Anti-VEGF Drugs Distributors List Table 105. Single-target Anti-VEGF Drugs Customers List Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Single-target Anti-VEGF Drugs Product Image Figure 2. Global Single-target Anti-VEGF Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Single-target Anti-VEGF Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Single-target Anti-VEGF Drugs Sales (2021-2032) & (K Units) Figure 5. Global Single-target Anti-VEGF Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Single-target Anti-VEGF Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Ranibizumab Image Figure 9. Conbercept Image Figure 10. Faricimab Image Figure 11. Brolucizumab Image Figure 12. Aflibercept Image Figure 13. Other Image Figure 14. Global Single-target Anti-VEGF Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Single-target Anti-VEGF Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2021-2032) Figure 17. Global Single-target Anti-VEGF Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Single-target Anti-VEGF Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2021-2032) Figure 20. Diabetic Retinopathy Image Figure 21. Age-related Macular Degeneration Image Figure 22. Other Image Figure 23. Global Single-target Anti-VEGF Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Single-target Anti-VEGF Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2021-2032) Figure 26. Global Single-target Anti-VEGF Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Single-target Anti-VEGF Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2021-2032) Figure 29. North America Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Single-target Anti-VEGF Drugs Sales Market Share by Country (2021-2032) Figure 31. U.S. Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Single-target Anti-VEGF Drugs Sales Market Share by Country (2021-2032) Figure 36. Germany Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Single-target Anti-VEGF Drugs Sales Market Share by Country (2021-2032) Figure 43. China Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Single-target Anti-VEGF Drugs Sales Market Share by Country (2021-2032) Figure 51. Brazil Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Single-target Anti-VEGF Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Single-target Anti-VEGF Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Single-target Anti-VEGF Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Figure 62. North America Single-target Anti-VEGF Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Europe Single-target Anti-VEGF Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Single-target Anti-VEGF Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Single-target Anti-VEGF Drugs Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Single-target Anti-VEGF Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Single-target Anti-VEGF Drugs Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Single-target Anti-VEGF Drugs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Ranibizumab
  • Conbercept
  • Faricimab
  • Brolucizumab
  • Aflibercept
  • Other
Applications
  • Diabetic Retinopathy
  • Age-related Macular Degeneration
  • Other
Companies covered
  • Roche
  • Chengdu Kanghong Pharmaceutical
  • Samsung Bioepis
  • Regeneron Pharmaceuticals
  • Novartis
  • Coherus BioSciences
  • Biocon Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Single-target Anti-VEGF Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Single-target Anti-VEGF Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Single-target Anti-VEGF Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Single-target Anti-VEGF Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Single-target Anti-VEGF Drugs Market Dynamics
  1. 2.1 Single-target Anti-VEGF Drugs Industry Trends
  2. 2.2 Single-target Anti-VEGF Drugs Industry Drivers
  3. 2.3 Single-target Anti-VEGF Drugs Industry Opportunities and Challenges
  4. 2.4 Single-target Anti-VEGF Drugs Industry Restraints
3 Single-target Anti-VEGF Drugs Market by Manufacturers
  1. 3.1 Global Single-target Anti-VEGF Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Single-target Anti-VEGF Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Single-target Anti-VEGF Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Single-target Anti-VEGF Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Single-target Anti-VEGF Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Single-target Anti-VEGF Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Single-target Anti-VEGF Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Single-target Anti-VEGF Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Single-target Anti-VEGF Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Single-target Anti-VEGF Drugs Tier 1, Tier 2, and Tier 3
4 Single-target Anti-VEGF Drugs Market by Type
  1. 4.1 Single-target Anti-VEGF Drugs Type Introduction
  2. 4.1.1 Ranibizumab
  3. 4.1.2 Conbercept
  4. 4.1.3 Faricimab
  5. 4.1.4 Brolucizumab
  6. 4.1.5 Aflibercept
  7. 4.1.6 Other
  8. 4.2 Global Single-target Anti-VEGF Drugs Sales by Type
  9. 4.2.1 Global Single-target Anti-VEGF Drugs Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Single-target Anti-VEGF Drugs Sales by Type (2021-2032)
  11. 4.2.3 Global Single-target Anti-VEGF Drugs Sales Market Share by Type (2021-2032)
  12. 4.3 Global Single-target Anti-VEGF Drugs Revenue by Type
  13. 4.3.1 Global Single-target Anti-VEGF Drugs Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Single-target Anti-VEGF Drugs Revenue by Type (2021-2032)
  15. 4.3.3 Global Single-target Anti-VEGF Drugs Revenue Market Share by Type (2021-2032)
5 Single-target Anti-VEGF Drugs Market by Application
  1. 5.1 Single-target Anti-VEGF Drugs Application Introduction
  2. 5.1.1 Diabetic Retinopathy
  3. 5.1.2 Age-related Macular Degeneration
  4. 5.1.3 Other
  5. 5.2 Global Single-target Anti-VEGF Drugs Sales by Application
  6. 5.2.1 Global Single-target Anti-VEGF Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Single-target Anti-VEGF Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Single-target Anti-VEGF Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Single-target Anti-VEGF Drugs Revenue by Application
  10. 5.3.1 Global Single-target Anti-VEGF Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Single-target Anti-VEGF Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Single-target Anti-VEGF Drugs Revenue Market Share by Application (2021-2032)
6 Global Single-target Anti-VEGF Drugs Sales by Region
  1. 6.1 Global Single-target Anti-VEGF Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Single-target Anti-VEGF Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Single-target Anti-VEGF Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Single-target Anti-VEGF Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Single-target Anti-VEGF Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Single-target Anti-VEGF Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Single-target Anti-VEGF Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Single-target Anti-VEGF Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Single-target Anti-VEGF Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Single-target Anti-VEGF Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Single-target Anti-VEGF Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Single-target Anti-VEGF Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Single-target Anti-VEGF Drugs Revenue by Region
  1. 7.1 Global Single-target Anti-VEGF Drugs Revenue by Region
  2. 7.1.1 Global Single-target Anti-VEGF Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Single-target Anti-VEGF Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Single-target Anti-VEGF Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Single-target Anti-VEGF Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Single-target Anti-VEGF Drugs Revenue (2021-2032)
  8. 7.2.2 North America Single-target Anti-VEGF Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Single-target Anti-VEGF Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Single-target Anti-VEGF Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Single-target Anti-VEGF Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Single-target Anti-VEGF Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Single-target Anti-VEGF Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Single-target Anti-VEGF Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche
  2. 8.1.1 Roche Company Information
  3. 8.1.2 Roche Business Overview
  4. 8.1.3 Roche Single-target Anti-VEGF Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Roche Single-target Anti-VEGF Drugs Product Portfolio
  6. 8.1.5 Roche Recent Developments
  7. 8.2 Chengdu Kanghong Pharmaceutical
  8. 8.2.1 Chengdu Kanghong Pharmaceutical Company Information
  9. 8.2.2 Chengdu Kanghong Pharmaceutical Business Overview
  10. 8.2.3 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Chengdu Kanghong Pharmaceutical Single-target Anti-VEGF Drugs Product Portfolio
  12. 8.2.5 Chengdu Kanghong Pharmaceutical Recent Developments
  13. 8.3 Samsung Bioepis
  14. 8.3.1 Samsung Bioepis Company Information
  15. 8.3.2 Samsung Bioepis Business Overview
  16. 8.3.3 Samsung Bioepis Single-target Anti-VEGF Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Samsung Bioepis Single-target Anti-VEGF Drugs Product Portfolio
  18. 8.3.5 Samsung Bioepis Recent Developments
  19. 8.4 Regeneron Pharmaceuticals
  20. 8.4.1 Regeneron Pharmaceuticals Company Information
  21. 8.4.2 Regeneron Pharmaceuticals Business Overview
  22. 8.4.3 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Regeneron Pharmaceuticals Single-target Anti-VEGF Drugs Product Portfolio
  24. 8.4.5 Regeneron Pharmaceuticals Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Single-target Anti-VEGF Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Single-target Anti-VEGF Drugs Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Coherus BioSciences
  32. 8.6.1 Coherus BioSciences Company Information
  33. 8.6.2 Coherus BioSciences Business Overview
  34. 8.6.3 Coherus BioSciences Single-target Anti-VEGF Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Coherus BioSciences Single-target Anti-VEGF Drugs Product Portfolio
  36. 8.6.5 Coherus BioSciences Recent Developments
  37. 8.7 Biocon Biologics
  38. 8.7.1 Biocon Biologics Company Information
  39. 8.7.2 Biocon Biologics Business Overview
  40. 8.7.3 Biocon Biologics Single-target Anti-VEGF Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Biocon Biologics Single-target Anti-VEGF Drugs Product Portfolio
  42. 8.7.5 Biocon Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Single-target Anti-VEGF Drugs Value Chain Analysis
  2. 9.1.1 Single-target Anti-VEGF Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Single-target Anti-VEGF Drugs Production Mode & Process
  6. 9.2 Single-target Anti-VEGF Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Single-target Anti-VEGF Drugs Distributors
  9. 9.2.3 Single-target Anti-VEGF Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst